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ABSTRACT
Pemphigus Vulgaris (PV) is an uncommon autoimmune and blistering mucocutaneous disease. Childhood Pemphigus 
Vulgaris (CPV) is a pediatric variant of PV, which affects children below 12 years, being very rare among children under 10 
years of age. CPV has similar clinical, histological, and immunological features as seen in PV in adults. The mucocutaneous 
clinical presentation is the most common in both age groups. Vesicles and erosions arising from the disease usually cause 
pain. A few CPV cases have been reported in the literature. This study reports a case of an 8-year-old male patient with 
oral lesions since the age of 3 years, and the diagnosis of pemphigus was achieved only 2 years after the appearance 
of the initial lesions. CPV remains a rare disease, making the diagnosis of this clinical case a challenge due to its age of 
onset and clinical features presented by the patient. Therefore, dentists and physicians should know how to differentiate 
CPV from other bullous autoimmune diseases more common in childhood. 
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INTRODUCTION
Pemphigus Vulgaris (PV) is an uncommon 
autoimmune blistering disease involving the skin 
and mucous membranes.1,2 Most patients with PV 
have circulating autoantibodies against desmogleins 
1 and 3, which are transmembrane proteins of the 
desmosomes. The clinical disorder is a consequence 
of the loss of cell adhesion, which occurs due to the 
attack on transmembrane proteins.3
Histopathological features are represented by 
intraepidermal acantholysis and intact basal layer.1 It is 
important to identify the level of bubble cleavage through 
histopathological examination to diagnose pemphigus and 
differentiate it from other subepidermal bullous lesions, 
as acantholytic keratinocytes can be observed in several 
vesiculobullous diseases (Hailey-Hailey-like Grover’s disease 
and Hailey-Hailey disease, among others).4
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PV has a pediatric variant divided into juvenile PV 
(JPV) and childhood PV (CPV). There is no difference 
between PV and CPV concerning the diagnostic tests 
because CPV has similar clinical, histological, and 
immunological features seen in PV in adults.2,3
Among bullous diseases in childhood, CPV is the 
least frequent entity and thus can be misdiagnosed.2 
The differential diagnosis of CPV includes (i) hand-foot-
mouth disease, (ii) oral candidiasis, (iii) acute herpetic 
gingivostomatitis, (iv) erythema multiforme, (v) Behcet’s 
disease, (vi) lichen planus, and (vii) recurrent aphthous 
stomatitis.5
Clinical presentation includes flaccid blisters that 
produce erosions after rupture. Anamnesis should 
focus on duration, number of lesions, and recurrence 
of symptoms.2
Ancillary diagnostic methods include biopsy 
with immunofluorescence (IF) investigation.2 Direct 
immunofluorescence (DIF) identifies the presence of 
autoantibodies and complement fractions.3,6 CPV 
therapy is performed with topical or systemic steroids 
combined with adjuvant immunosuppressive drugs 
due to steroid-sparing effects.3,6
This study has the academic importance of 
reporting a case of CPV with aggressive clinical 
presentation in a male child.
CASE REPORT
An 8-years-old black male patient sought care 
in the stomatology clinic after looking for medical 
care without a definitive diagnosis and therapeutic 
success. His mother reported that the initial lesions 
appeared at the age of 3 years, initially in the tongue, 
then in other oral cavity areas. However, upon current 
examination, the patient presented mouth opening 
limitation, sialorrhea, and ulcers in the oral mucosa, 
glans, and lower eyelids, as well as urethral secretion. 
Oral lesions involved the upper and lower lip mucosa, 
the tongue’s ventral surface, hard palate, soft palate, 
oral commissures, lower alveolar mucosa, oral mucosa, 
and upper and lower gums (Figure 1).
The patient also presented speech difficulties 
accompanied by hoarseness. Laryngoscopy showed 
ulcerations in the larynx and pharynx. Incisional 
biopsy in the lower labial mucosa was performed. The 
histopathological report showed PV and DIF confirmed 
the diagnosis with positive detection of intercellular 
IgG3 (Figure 2).
Initial treatment comprised prednisone (1mg/kg/
day) and Dapsone (1 mg/kg/day). Six months after 
treatment, only oral lesions remained, but the clinical 
condition worsened the next month, and lesions in the 
genital mucosa relapsed. At this moment, prednisone 
(1mg/kg/day) and dapsone (1 mg/kg/day) were again 
prescribed until achieving clinical regression of genital 
lesions. With the eighth month of follow-up, ulcers 
were present only in the mouth and, in the ninth 
month of follow-up, the clinical mouth condition had 
improved, but lesions in the palate persisted. After a 
short time, ulcers in other sites reappeared.
When the patient completed one year and three 
months of treatment, the initial treatment, prednisone 
was gradually tapered to a maintenance dose of 
12.5 mg daily, and dapsone was withdrawn due to 
side effects. At this moment, infection was diagnosed 
in the oral cavity and other sites of the patient’s body. 
Thus sulfamethoxazole (200 mg) and trimethoprim 
(40 mg) BID were prescribed. This new therapeutical 
approach was applied to achieve clinical regression of 
the lesions.
To date, the patient of this clinical case presented 
marked weight gain and growth retardation, even 
with the use of a steroid-sparing drug and a decrease 
in steroid dosage.
In the last follow-up, lesions in the eyelids, 
larynx, pharynx, and glans had disappeared without 
relapse. However, ulcers of the oral cavity remain in 
the lower labial mucosa and ventral surface of the 
tongue (Figure 3). In addition to systemic medications, 
topical corticosteroid on the remaining oral lesions 
was added to the therapeutic regimen. The patient 
currently completed a clinical follow-up of 2 years 
and 10 months, and his clinical status substantially 
improved.
DISCUSSION
This article describes a case of CPV with aggressive 
behavior. CPV accounts for approximately 1.4-3.7% 
of all PV cases. It is rare in children under 10 years of 
age. The age of onset comprises children under the 
age of 12 years, being lower in boys than in girls.1-3,5,7,8 
Pemphigus in children younger than 12 years is known 
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as childhood pemphigus, and in those aged between 
12-18 years as juvenile pemphigus.7 PV in children 
remained a rare disease since 1955 when the first 
case of PV in the pediatric age was reported. Since 
then, approximately 50 new cases have been reported 
to date.9 Interestingly, our patient’s initial lesions 
appeared when he was 3 years old, and the definite 
diagnosis was made 2 years after the first clinical signs.
Numerous vesicles and painful erosions in the 
oral cavity clinically characterize PV. One of the first 
symptoms is intense pain associated with difficulty 
in defecating, urinating, and ingesting foods and 
liquids.3,6 The painful symptomatology in this patient 
remained absent throughout the clinical course of 
the disease, allowing the child to feed and urinate 
normally, unlike most clinical cases reported in the 
literature.
The etiology of pemphigus vulgaris is uncertain. 
In some cases, it may have a strong genetic basis as 
it has been more frequently reported in certain racial 
Figure 1. Lesions at the first appointment. A – Ulcerative lesions in the ventral surface of the tongue; B – Lesions 
with an ulcerative surface in lower labial mucosa (biopsy site); C – Ulcers in glans and foreskin; D – Ulcer in the 
mucosa of the lower eyelid.
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groups. Although the exact etiology remains obscure, 
a wide range of antigenic factors, including drugs, 
herpes virus and bacterial infections, and malignancy, 
have been suggested as triggering factors.10,11,13
The most frequently affected areas include the 
skin or mucous membranes of the oral cavity, anus, 
conjunctiva, and genital areas. An important difference 
between adult and pediatric PV is the high incidence 
of genital and ocular involvement in the pediatric 
variant.3 In addition, CPV has a more variable clinical 
course when compared to PV in adults.3,4 When the 
pharynx and larynx are involved, hoarseness may be 
present.1 In this case, lesions affected the same mucosa 
areas described in the literature. Due to the presence 
of hoarseness among our patient’s clinical features, a 
laryngoscopy was performed and showed the presence 
of ulcers in the larynx and pharynx.
The majority of patients with CPV have lesions in 
both mucosa and skin, with the appearance of oral 
lesions being the first manifestation of the disorder.3,4 
Ulcers in the oral mucosa were the first sign of the 
disease of this case report, followed by the mucous 
membranes of the conjunctiva and glans. However, 
skin lesions did not appear at any stage of the disease.
According to Surya et al.,2 oral lesions usually 
affect gingiva, oral mucosa, lips, hard and soft palate.2 
In addition to these areas, oral lesions also affected 
the ventral surface of the tongue and lower alveolar 
mucosa. These authors also reported that the diagnosis 
could be performed either by routine histopathology 
or DIF, but the recommendation is to perform both.
The differential diagnosis of PV in children 
includes entities affecting the mucocutaneous tissues 
or only the mucous membranes, some affecting only 
the oral cavity. The mucocutaneous dermatological 
diseases include (i) bullous epidermolysis, (ii) linear IgA 
disease, (iii) paraneoplastic pemphigus, (iv) erythema 
multiforme, (v) cicatricial pemphigoid, (vi) erosive 
lichen planus.14
Recurrent aphthous stomatitis and acute herpetic 
gingivostomatitis present signs only in the oral mucosa. 
There is the appearance of ulcers with a yellowish 
base in the former, surrounded by an erythematous 
halo, with regular margins and disappearance without 
treatment, which characterizes an acute course. 
The second one is characterized by small yellowish 
vesicles that break quickly, giving rise to ulcers with 
an erythematous halo affecting the free and adherent 
Figure 2. Photomicrographs of the biopsy specimen. A – Intraepithelial blister with a single layer of basal cells 
recovering the conjunctive tissue and lymphoplasmacytic inflammatory infiltrate with eosinophils (H&E, 5X); B – High 
magnification of image A (H&E, 20X); C – Ulcered area with grouped acantholytic cells (*) with degenerative 
alterations (H&E, 40X); D – View of the inferior area of epithelial blister and suprabasal slit showing tiny area with 
rare basal cells still attached to the conjunctive tissue (H&E, 40X); E – Positive direct immunofluorescence showing 
IgG3 in the intercellular space of cells of the remaining epithelium basal layer on the conjunctiva.
Lins Filho GT, Barbosa NLS, Abreu EMV, et al.
5-8Autops Case Rep (São Paulo). 2021;11:e2021267
gums.14 Knowing that the appearance of oral lesions is 
the first sign of PV in most patients, the physician needs 
to be acquainted with these diseases’ characteristics 
to differentiate them from PV, avoiding a delay in 
diagnosis.
Behçet’s disease compromises the oral, genital 
and ocular mucous membranes.14 This disease was the 
main differential diagnosis of this clinical case because 
the patient attended the first consultation with lesions 
on these areas.
Biopsies performed on intact blisters provide better 
results, but these are rarely found since they rupture 
easily. When the specimen is taken from the center of 
the ulcerative lesion, it is histopathologically nonspecific. 
For precise DIF diagnosis and histopathological exam, 
biopsy has to be performed in the perilesional area.2,10 
A single biopsy was performed in the perilesional area 
of the labial lesion in the patient of this case report. 
The biopsy specimen was split into two parts that were 
sent for histopathological and DIF evaluation.
Figure 3. Lesions on the last follow-up. A – Ulcerative lesions in the ventral surface of the tongue; B – Ulcers in 
the transition between alveolar mucosa and lower labial mucosa; C – Remission of lesions in glans and foreskin; 
D – Absence of lesion in the lower eyelid.
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When lesions are exclusively presented in the 
mucosa, IgG autoantibodies are directed against Dsg 
3, an autoantigen of greater expression in the lower 
portions of mucosal squamous epithelium. DIF analysis 
makes it possible to observe an intercellular fluorescent 
IgG distribution, usually found in the lower layers of 
the epithelium. The method works due to an antigen-
antibody reaction in vitro. Radiation-absorbing dyes 
(fluorochromes excited by ultraviolet) shine when tissue 
deposition of IgG occurs.4,10,12
There are three laboratory diagnostic tests 
related to antibodies. Direct Immunofluorescence 
is an exam considered as the “gold standard” for 
pemphigus diagnosis. The Indirect Immunofluorescence 
technique determines the presence of circulating 
autoantibodies in the serum and assists in diagnosis. 
Finally, the Immunohistochemical examination 
consists of a combination of immunological and 
histological methods for detecting specific antigens 
in tissues or cells (immunocytochemistry), based on 
the identification of the antigen-antibody complex. 
Markers for the detection of intercellular IgG and C3 
can be used in PV. These last two techniques were 
not used because the main diagnostic hypothesis was 
PV since the first consultation of the patient with the 
specialist in Oral Medicine. Therefore, the biopsy was 
performed to the conventional histological analysis 
and DIF. These techniques were chosen to take into 
account recommendations by most authors.4,9
Genital lesions have as differential diagnosis (i) 
sexual abuse, (ii) bullous fixed drug eruption, and 
(iii) bullous lichen sclerosis.1 At the patient’s first 
appointment, rapid tests were performed for Hepatitis 
B, Hepatitis C, HIV, and Syphilis, which showed 
negative results.
A delay in diagnosing CPV often occurs due to 
the rarity of PV in this age group and similar clinical 
appearance with other bullous and ulcerative diseases 
that affect the oral cavity. In this context, a brief history 
and clinical examination can lead to incorrect diagnosis 
and, consequently, to inadequate treatment.2,5 A recent 
case report also reported a delay in diagnosing PV in 
a child. The authors reported that it is possible due to 
the wide variety of blistering diseases most prevalent 
and the lack of familiarity with this entity.9 The patient 
in this case report had only oral lesions when he was 
initially evaluated by a physician, a fact that may 
have hindered the diagnosis. It also emphasizes the 
importance of the differential diagnosis of CPV.
The basis of PV treatment is systemic corticosteroids, 
as they present potent anti-inflammatory and 
immunosuppressive action. The most frequently 
used oral steroids for PV treatment is prednisone, 
followed by prednisolone. Most authors prefer the 
administration of full doses (1 to 2 mg/ kg/ day) since 
the beginning of the therapy, thus avoiding progressive 
dose increase.4 In children, the dose should be chosen 
according to age, weight, disease severity, and drug 
side-effects. Prednisolone dosage is adjusted according 
to the clinical response and slowly reduced in cases 
showing improvement.5,13
Immunomodulating drugs can also be used as 
steroid-sparing agents due to common side effects 
after prolonged use of corticosteroids and enhance 
therapeutic response. The search for adjunctive 
treatments with immunomodulators was encouraged 
to reduce the dose and duration of treatment with 
corticosteroids. A common steroid-sparing drug 
used in pemphigus therapy is dapsone. Drugs can 
be stopped when lesions disappear, but, usually, 
in pediatric patients, pemphigus shows a relapsing 
course as observed in adults, and total remission 
is rare. Therefore, maintenance dose (5–20 mg/
dl) may be required in some patients.2,5,13 In the 
present case report, dapsone was interrupted due 
to side effects. Dapsone is withdrawn due to its 
potential hematological adverse effects, such as 
methemoglobinemia, hemolysis, and agranulocytosis. 
These effects are mandatory and vary only in intensity.15 
They are classified as dose-dependent effects. A study 
revealed that this drug was the most common cause 
of acquired methemoglobinemia, which is caused by 
hydroxylamine, a dapsone metabolite.16
Although sulfamethoxazole-trimethoprim is not 
a drug of treatment for pemphigus vulgaris, this drug 
was prescribed to our patient because he presented 
infection in different body sites. Sulfamethoxazole-
trimethoprim was prescribed due to its ability to control 
superinfections, mainly by Staphylococcus aureus, and 
also due to the indirect immunomodulatory effect, 
regulating the secretion of IL-1 and TNF-α.17
Although there is scarce scientific evidence on 
the efficacy of different immunomodulatory drugs,5 
satisfactory result was achieved in this case, even in 
the absence of the lesions’ complete remission. To 
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support this statement, some facts must be considered: 
the complete CPV remission is rare, recurrences are 
common,5 and the patient’s disease was misdiagnosed 
for 2 years.
Some patients are refractory to conventional 
therapy or become chronically steroid-dependent, so 
there is a need for new therapeutic options to treat 
pediatric PV.1 Since July 2018, rituximab was labeled 
by the US Food and Drug Administration (FDA) to 
refractive severe-to-medium pemphigus patients and 
adapted a year later by the European Committee health 
authorities.8,18 Thereby, a previous case report of a 
14-year-old girl was treated with a modified two-dose 
regimen, performed 30 days apart, exceptionally due to 
financial reasons. This therapeutical approach proved 
highly efficient and long-standing, which encourages 
its further implementation.8 In addition, a case series 
concluded regarding the terms of efficacy and safety of 
rituximab. Increasing evidence supports that rituximab 
is a good treatment choice, not only in adults but also 
in pediatric patients with pemphigus.18 The treatment 
with rituximab was not applied in the index case due 
to financial restraints.
Due to the patients’ growth and development 
in childhood, the frequency of side effects of the 
high doses and prolonged use of steroids is higher in 
children than in adults. The most common are growth 
retardation, infection, obesity, social and psychological 
distress.1,3,6
Despite the use of numerous immunosuppressive 
therapies and a better prognosis of CPV concerning PV, 
some patients are refractory to conventional treatment, 
as occurred in this case report, or may become steroid-
dependent. Therefore, new therapeutic options 
for pediatric PV are expected.1,3 In the last years, 
some case reports described that the rituximab can 
be considered an effective adjuvant therapy when 
treating resistant vesiculobullous disorders in pediatric 
patients. However, a greater number of patients and 
long-term follow-up is required to propose a definite 
conclusion.1,6-8,18,19
CONCLUSION
In conclusion, CPV diagnosis is still challenging due 
to the varied clinical features and the clinical similarity 
to other pediatric autoimmune bullous diseases. These 
characteristics were observed in this case report, 
which presented extensive painless lesions at different 
sites of mucous membranes and late diagnosis. It 
demonstrates the importance of reporting new CPV 
cases. A better understanding of CPV characteristics, 
such as the fact that oral involvement can be the first 
signal of the disease and how to diagnose it, enables 
the correct diagnosis, leading to earlier detection of 
the disease and indication of appropriate therapy.
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